Dianthus Therapeutics Inc. (NASDAQ:DNTH) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On ...
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.
We recently compiled a list of the Top 10 Boring Stocks That Make Money. Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among ...
Dianthus Therapeutics Inc. DNTH shares are up during Monday’s premarket session following an early GO decision announced by the company based on an interim responder analysis in the Phase 3 CAPTIVATE ...
Add Yahoo as a preferred source to see more of our stories on Google. Pink dianthus flower Dianthus are easy plants to care for and deadheading their ruffled and aromatic blooms during the summer ...
Investor's Business Daily on MSN
Dianthus Therapeutics has appreciated 12-fold over two years. What's going on?
Dianthus Therapeutics stock shot higher Monday after the company said it would advance its experimental CIDP treatment.
Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe ...
Early GO decision reached in CAPTIVATE ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned ...
14d
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
Dianthus intends to use the net proceeds from this offering to advance the Company’s clinical and preclinical development activities, commercial readiness activities as well as for working capital and ...
Dianthus Therapeutics is on a mission to reduce the number of injections autoimmune disease patients have to receive, using $100 million in series A financing to send its antibody candidate into the ...
Magenta Therapeutics and Dianthus Therapeutics announced a merger to form a company that will advance the latter’s next-generation complement inhibitor pipeline. The combined company will take on the ...
Dianthus Therapeutics is advancing its challenge for the increasingly competitive generalized myasthenia gravis (gMG) market, outlining plans to move into phase 3 on the back of hits in a midphase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results